Semaglutide vs Tirzepatide: A Clinical Evidence Comparison

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two most prescribed peptide-based weight-loss drugs in the world. Both target GLP-1 receptors, but tirzepatide adds GIP receptor agonism — making it a "twincretin." The question patients and clinicians keep asking: which one is better?

The answer depends on what "better" means.

Weight loss: tirzepatide leads

The headline numbers favor tirzepatide. In the SURMOUNT-1 trial (2022), tirzepatide at the highest dose (15 mg) produced 22.5% mean weight loss over 72 weeks. In the STEP 1 trial (2021), semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks.

A direct head-to-head — the SURPASS-2 trial — compared tirzepatide to semaglutide 1 mg (the diabetes dose, not the obesity dose) and showed tirzepatide superiority at all dose levels.

The comparison isn't perfectly clean because the obesity-dose head-to-head (tirzepatide 15 mg vs semaglutide 2.4 mg) hasn't published Phase 3 results at the time of writing. But the available data consistently shows tirzepatide producing 3-7 percentage points more weight loss than semaglutide.

Cardiovascular outcomes: semaglutide has the data

This is where semaglutide holds a significant advantage. The SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in overweight/obese adults without diabetes. This is a hard clinical endpoint — heart attacks, strokes, and cardiovascular death — not a surrogate marker.

Tirzepatide does not yet have completed cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing. Until it reports, semaglutide is the only GLP-1 receptor agonist with proven cardiovascular benefit in non-diabetic obesity.

For patients whose primary concern is cardiovascular risk reduction rather than maximal weight loss, this distinction matters.

Side effect profiles

Both drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, and constipation. These are dose-dependent and typically improve over 4-8 weeks of titration.

Comparative data suggests similar tolerability profiles, though tirzepatide may have slightly lower nausea rates at equipotent doses — possibly because GIP agonism partially buffers the GLP-1 gastrointestinal effects.

Both carry warnings for thyroid C-cell tumors (based on rodent data), pancreatitis risk, and gastroparesis. Neither should be used during pregnancy.

Mechanism differences

Semaglutide is a pure GLP-1 receptor agonist. It's a modified version of human GLP-1 with amino acid substitutions and an albumin-binding fatty acid chain that extends the half-life to ~7 days.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It's built on the GIP backbone with modifications that also activate the GLP-1 receptor. The GIP component has independent effects on fat metabolism and may contribute to the greater weight-loss efficacy.

Whether dual agonism is categorically better remains debated. GIP's role in energy balance is complex — in isolation, GIP receptor agonism can be either anabolic or catabolic depending on context. The net effect in tirzepatide clearly favors weight loss, but the mechanistic reasons are still being worked out.

Formulations and availability

Semaglutide is available as:

• Weekly subcutaneous injection (Ozempic for diabetes, Wegovy for obesity)
• Daily oral tablet (Rybelsus for diabetes)

Tirzepatide is available as:

• Weekly subcutaneous injection (Mounjaro for diabetes, Zepbound for obesity)

Both face ongoing supply constraints. Tirzepatide availability has been more limited, though manufacturing capacity is expanding.

Cost

List prices are comparable — roughly $1,000-$1,400/month without insurance in the US. Insurance coverage varies significantly by plan and indication (diabetes vs. obesity). Both manufacturers offer savings programs.

The cost-effectiveness calculation depends on whether the additional ~5% weight loss from tirzepatide justifies any difference in out-of-pocket cost for a given patient.

Which one to choose

Choose semaglutide if: cardiovascular risk reduction is a primary goal (SELECT data), you prefer having an oral option (Rybelsus), or your insurance covers it more favorably.

Choose tirzepatide if: maximal weight loss is the primary goal, you've plateaued on semaglutide, or your insurance covers it more favorably.

The honest answer: for most patients, whichever one your insurance covers and your provider prescribes is the right choice. Both produce clinically meaningful weight loss that far exceeds any other pharmacological intervention. The difference between 15% and 22% weight loss is real, but both numbers represent transformative outcomes.

The next generation — retatrutide (triple agonist: GLP-1/GIP/glucagon) — may shift this comparison again. Phase 2 data showed up to 24% weight loss at 48 weeks. But Phase 3 data isn't available yet, so the current decision remains a two-drug question.